NasdaqGS:ACADBiotechs
Why ACADIA Pharmaceuticals (ACAD) Is Down 9.1% After EU Setback on Trofinetide Approval Effort
In late February and early March 2026, ACADIA Pharmaceuticals reported higher full-year 2025 earnings, issued 2026 revenue guidance of US$1.22–1.28 billion, received a negative CHMP opinion on trofinetide for Rett syndrome in the EU, and added experienced finance executive Jonathan M. Poole to its Board and Audit Committee.
The CHMP’s refusal of trofinetide, despite a pivotal trial meeting its key endpoints, raises important questions about ACADIA’s ability to expand Rett syndrome treatment...